Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
MNOV's Cash to Debt is ranked higher than
90% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. MNOV: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MNOV' s Cash to Debt Range Over the Past 10 Years
Min: 0.67  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
MNOV's Interest Coverage is ranked higher than
83% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNOV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNOV' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 3.39
M-Score: -3.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -35.23
MNOV's ROE (%) is ranked lower than
54% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. MNOV: -35.23 )
Ranked among companies with meaningful ROE (%) only.
MNOV' s ROE (%) Range Over the Past 10 Years
Min: -73.58  Med: -42.52 Max: -19.99
Current: -35.23
-73.58
-19.99
ROA (%) -29.31
MNOV's ROA (%) is ranked lower than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. MNOV: -29.31 )
Ranked among companies with meaningful ROA (%) only.
MNOV' s ROA (%) Range Over the Past 10 Years
Min: -52.77  Med: -30.28 Max: -16.41
Current: -29.31
-52.77
-16.41
ROC (Joel Greenblatt) (%) -7083.61
MNOV's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. MNOV: -7083.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNOV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -20467.29  Med: -4165.25 Max: -108.93
Current: -7083.61
-20467.29
-108.93
EBITDA Growth (3Y)(%) -29.60
MNOV's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. MNOV: -29.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNOV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -83.3  Med: -29.60 Max: 188.9
Current: -29.6
-83.3
188.9
EPS Growth (3Y)(%) -31.70
MNOV's EPS Growth (3Y)(%) is ranked lower than
81% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. MNOV: -31.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNOV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -86.2  Med: -26.90 Max: 254
Current: -31.7
-86.2
254
» MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MNOV Guru Trades in Q1 2015

Jim Simons 110,800 sh (-4.32%)
» More
Q2 2015

MNOV Guru Trades in Q2 2015

Jim Simons 115,700 sh (+4.42%)
» More
Q3 2015

MNOV Guru Trades in Q3 2015

Jim Simons 103,100 sh (-10.89%)
» More
Q4 2015

MNOV Guru Trades in Q4 2015

Jim Simons 98,200 sh (-4.75%)
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.65
MNOV's P/B is ranked lower than
68% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. MNOV: 3.65 )
Ranked among companies with meaningful P/B only.
MNOV' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 1.01 Max: 4.68
Current: 3.65
0.18
4.68
Current Ratio 18.77
MNOV's Current Ratio is ranked higher than
89% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. MNOV: 18.77 )
Ranked among companies with meaningful Current Ratio only.
MNOV' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 9.19 Max: 49.29
Current: 18.77
1.31
49.29
Quick Ratio 18.77
MNOV's Quick Ratio is ranked higher than
89% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. MNOV: 18.77 )
Ranked among companies with meaningful Quick Ratio only.
MNOV' s Quick Ratio Range Over the Past 10 Years
Min: 1.31  Med: 9.19 Max: 49.29
Current: 18.77
1.31
49.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.81
MNOV's Price/Net Cash is ranked lower than
55% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. MNOV: 6.81 )
Ranked among companies with meaningful Price/Net Cash only.
MNOV' s Price/Net Cash Range Over the Past 10 Years
Min: 0.71  Med: 4.71 Max: 30.33
Current: 6.81
0.71
30.33
Price/Net Current Asset Value 6.49
MNOV's Price/Net Current Asset Value is ranked lower than
56% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. MNOV: 6.49 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MNOV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.69  Med: 4.32 Max: 20.79
Current: 6.49
0.69
20.79
Price/Tangible Book 6.21
MNOV's Price/Tangible Book is ranked lower than
65% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. MNOV: 6.21 )
Ranked among companies with meaningful Price/Tangible Book only.
MNOV' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.4  Med: 3.27 Max: 54.67
Current: 6.21
0.4
54.67
Earnings Yield (Greenblatt) (%) -8.24
MNOV's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. MNOV: -8.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNOV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -8.36  Med: 99.80 Max: 8448.3
Current: -8.24
-8.36
8448.3

More Statistics

Revenue(Mil) $6
EPS $ -0.34
Beta-0.05
Short Percentage of Float2.90%
52-Week Range $2.62 - 5.90
Shares Outstanding(Mil)29.96

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RMN.Germany, 4875.Japan,
MediciNova Inc was incorporated in the State of Delaware on September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single industry segment - the discovery and development of small molecule therapeutics. Its core program includes, MN-001 (NASH), MN-166 (Neurology Diseases) and MN-221 (Respiratory Diseases). Its non-core programs include, MN-001 (Bronchial Asthma), MN-001 (Interstitial Cystitis), MN-029 (Cancer) and MN-221 (Preterm Labor). The Company is subject to government regulations, in the U.S., the FDA, under the Federal Food, Drug and Cosmetic Act, as amended, and other federal statutes and regulations.
» More Articles for MNOV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the... Feb 11 2016
MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in... Feb 07 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Jan 27 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Jan 27 2016
FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment... Jan 18 2016
FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment... Jan 18 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride... Jan 13 2016
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride... Jan 13 2016
MNOV: Positive Interim Safety and Clinical Data Presented at 26th International Symposium on ALS/MND Dec 16 2015
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of... Dec 16 2015
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of... Dec 16 2015
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride... Dec 14 2015
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride... Dec 14 2015
MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of... Dec 13 2015
MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of... Dec 13 2015
MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use... Dec 09 2015
MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use... Dec 09 2015
MEDICINOVA INC Financials Dec 08 2015
MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th... Dec 06 2015
MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th... Dec 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK